Background: There is increasing evidence showing that extracellular nucleotides may be important mediators of vascular inflammation. Nucleotide triphosphate diphosphohydrolase-1 (NTPDase-1, identical to CD39), the major vascular endothelial ectonucleotidase, is responsible for the hydrolysis of both extracellular ATP and ADP in the blood plasma to AMP. Studies were therefore conducted to evaluate the role of vascular NTPDase-/cd39 in modulating platelet activation and vascular injury in cardiac xenografts. Materials and Methods: Cardiac xenografts from both wild-type and cd39 knockout mice (C57BL/6 X 129 Svj) were transplanted into Lewis rats. Alterations in cd39 mRNA transcripts and NTPDase activity expression were evaluated in wild-type grafts in untreated rats and then following complement depletion and immunosuppression. Rejection responses were studied with both mutant and wildtype grafts in the following models: presensitization with or without complement depletion, comple-
Introduction
Vascular injury and platelet activation with consequent sequestration are significant pathological features in all forms of xenograft rejection (1) (2) (3) (4) . This process is further potentiated by molecular barriers between species and the loss of protective thromboregulatory elements from the vasculature (3) . This modality of xenograft injury is important, as specifically targeting platelet aggregation and blocking thrombin activity prolong graft survival (5) (6) (7) .
A major thromboregulatory element associated with the vascular endothelium is the ectonucleotidase termed nucleoside triphosphate diphosphohydrolase-I (NTPDase-1; ATPDase or EC 3.6.1.5). This ectoenzyme has the capacity to metabolize ATP and ADP to AMP (8) (9) (10) (11) . AMP is further converted to adenosine by 5' nucleotidase (12) . We and others have demonstrated that CD39, originally characterized as an activation marker on B cells (13) , has identity to the vascular ATPDase or NTPDase-1 (8, (14) (15) (16) .
NTPDase-1 plays a critical role in the regulation of platelet thrombosis and blood fluidity (8, 15, 16) , at least in part by modulating purinergic receptors expressed on leukocytes, platelets, and endothelium (17, 18) . Nucleotides are released from activated endothelial cells (EC) and are also secreted in high concentrations by platelets following their stimulation with exogenous ADP, collagen, thrombin, or activated complement components (10, 19) . Purinergic mediators may be responsible for recruitment with sequestration of activated platelets in the microvasculature and could also play a role in EC activation responses (1) . For instance, ADP is a potent agonist of platelet aggregation following activation of type 2 purinergic (P2) receptors (18, 19) . ATP also induces pore formation in cell membrane following P2X7 receptor stimulation (20, 21) . Both ATP and ADP stimulate various cell types, generally in a proinflammatory manner (22) (23) (24) (25) . Therefore, decreases in extracellular ATP and ADP mediated by CD39 tend to abrogate aggregatory and proinflammatory stimuli (8, 9, 23) . Furthermore, adenosine functions as an antithrombotic and anti-inflammatory stimulus (18, 26) , providing a second mechanism by which NTPDase-1 down-regulates platelet aggregation and inflammation, by providing AMP for 5 '-nucleotidase action (1, 12, 26) .
Hyperacute rejection (HAR) is caused by the reaction of recipient xenoreactive natural antibodies and complement with the EC lining the discordant xenograft vasculature (1, 4, 27, 28) . If HAR is abrogated, another phase of rejection leads to graft loss around days [3] [4] by a process referred to as delayed xenograft rejection (DXR) (3, 27, 28) . Accommodation refers to the survival of a graft in the presence of anti-graft antibodies and complement (4) . This can be studied by inducing complement depletion and administering cyclosporin A (CsA) in concordant small animal combinations (3, 4) .
We have already established that vascular ATPDase/CD39 expression may be rapidly decreased by reperfusion injury (29) , oxidant stress (8, 30) , or cytokine-mediated EC activation responses as seen in xenograft rejection (31, 32 
Histology and Immunohistology
The xenografts were snap frozen and stored at -80°C or fixed in neutral-buffered formaline for hematoxylin and eosin staining. Hematoxylin and eosin stains were done in paraffin sections; immunostainings were performed on cryostat sections, counterstained with hematoxylin. Expression of CD39 was visualized using rabbit polyclonal antibody generated specifically against mouse ATPDase (18) . Detection of P-selectin as a surrogate marker for platelet sequestration was carried out using rabbit anti-mouse/rat P-selectin polyclonal antibodies (Pharmingen, San Diego, CA). (Fig. 2A) . However, comparable levels of immunoreactive cd39 were observed on Western blotting (Fig. 3A) and by immunostaining performed on histological sections at all time points sampled to rejection (Fig. 4B) .
Cardiac rejection was associated with vascular thrombosis, edema, myocardial necrosis, and host leukocyte infiltration (Fig. 4A) . P-selectin staining revealed platelet sequestration with evidence for microvascular thrombosis in rejected grafts (Fig. 4C) .
Accommodated Wild-type Xenografts
As before, levels of cd39 post-transcripts were initially comparable in grafts transplanted into complement-depleted and immunosuppressed rats (0.79 ± 0.06 at baseline and 0.63 ± 0.33 AU at 1 hr) but then also substantially increased at the 12-hr post-transplantation time point. In contrast to the rejecting grafts, levels then gradually increased to much higher levels associated with prolonged graft survival (3.73 ± 0.27 AU at 60 days) (Fig. 1) (Fig. 5) . Analysis by Western blot showed that cd39 levels increased parallel to NTPDase activity within this incremental phase (Fig. 3B) and again during the period of prolonged survival (Fig. 6A) (Fig. 8A) . Moderate-sized healing infarctions in the ventricular walls were observed at 75 days after transplantation (Fig. 9) . There was no detection of cd39 in knockout grafts; infiltrating rat cells did not stain with the anti-mouse cd39 antibodies used (Fig. 8B) . P-selectin expression was observed mainly in the intravascular space, in association with platelet sequestration (Fig. 8C) transplantation (Fig. 2) in a manner analogous to that observed for ischemia reperfusion injury (29) and exposure to oxidant stress (8, (30) (31) (32) (Fig. 3A) and immunostaining (Fig. 4B) confirmed that immunoreactive cd39 is expressed on rejected cardiac xenografts. However, concurrent determinations of cd39 mRNA levels ( Fig. 1) and NTPDase activity ( Fig. 2A) revealed dramatic decreases in the rejected grafts. We have previously shown in other systems that levels of cd39 immunoreactivity do not directly correlate with the substantial and simultaneous decreases in the specific expression of NTPDase biochemical activity (31, 38, 39) . We suggest that the persistent expression of immunoreactive cd39 protein does not indicate the full potential for biochemical activity. Thus, active site perturbation of the NTPDase with loss of activity may occur with maintenance of immunoreactive epitopes within the C-terminal regions.
There were no differences between wildtype (cd39"'+) and knockout (cd39-'-) xenograft survival times with respect to hyperacute rejection (presensitized), concordant xenograft rejection (unmodified host), and delayed xenograft rejection models (see Table 1 ). However, mutant cardiac xenografts were observed to undergo a form of delayed rejection with more rapid vascular occlusion than for matched wild-type organs. These events were observed when these grafts were performed in sensitized rats depleted of complement by using CVF ( NTPDase activities of naive nongrafted hearts of both groups of mice were almost at the same levels (Fig. 5) . These data may suggest that total ectonucleotidase activities are compensated by NTPDases other than but related to cd39, for example, cd3914 and cd3911. However, NTPDase activities of wild-type grafts increased over 3-fold in accommodated grafts when compared to baseline. Biochemical activities did not increase to 60 days after transplantation in the mutant grafts despite mononuclear cellular infiltration (Figs. 5,  8 ). This observation further suggests either that other cell-associated NTPDases do not become induced within these grafts or they are solubilized and lost.
All surviving grafts from the cd39 null mice (n = 4) had P-selectin staining at 45 days posttransplantation. Wild-type accommodated grafts (n = 6) did not express P-selectin even up to 75 days after transplantation (data not shown). Infarction was observed only in mutant grafts (Fig. 9 ). These observations suggest that the process of accommodation requires NTPDase activity to maintain vascular integrity of the graft and mitigate against platelet sequestration. However, other NTPDases expressed in the mutant cardiac grafts appear to compensate, at least in part, for the loss of cd39 and thereby facilitate this extent of survival.
Previous studies indicated that potato apyrase administration (40) and CD39 adenovirus-mediated gene transfer into endothelial cells (41) prolong discordant xenograft survival. Our results also suggest that the intrinsic overexpression of NTPDase activity in surviving xenografts has beneficial effects with respect to the potential for vascular injury and platelet activation. We conclude that NTPDase-1 may play a role in the maintenance of vascular integrity and control of thrombosis in xenografts.
